Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E48.88 EPS (ttm)1.46 Insider Own0.10% Shs Outstand2.68B Perf Week-1.55%
Market Cap191.08B Forward P/E15.26 EPS next Y4.67 Insider Trans-29.03% Shs Float2.66B Perf Month1.14%
Income3.94B PEG5.49 EPS next Q1.13 Inst Own76.00% Short Float0.65% Perf Quarter13.16%
Sales41.26B P/S4.63 EPS this Y29.20% Inst Trans0.12% Short Ratio2.15 Perf Half Y20.88%
Book/sh12.12 P/B5.88 EPS next Y8.81% ROA1.50% Target Price75.75 Perf Year12.44%
Cash/sh2.83 P/C25.16 EPS next 5Y8.90% ROE3.90% 52W Range52.83 - 72.89 Perf YTD26.57%
Dividend1.92 P/FCF11942.70 EPS past 5Y-1.90% ROI8.70% 52W High-2.29% Beta0.88
Dividend %2.70% Quick Ratio1.00 Sales past 5Y-3.20% Gross Margin68.00% 52W Low34.81% ATR1.31
Employees69000 Current Ratio1.30 Sales Q/Q5.40% Oper. Margin12.30% RSI (14)54.19 Volatility2.81% 1.71%
OptionableYes Debt/Eq0.72 EPS Q/Q-10.50% Profit Margin3.30% Rel Volume1.13 Prev Close69.46
ShortableYes LT Debt/Eq0.61 EarningsOct 25 BMO Payout377.30% Avg Volume8.11M Price71.22
Recom1.90 SMA200.70% SMA502.63% SMA20016.01% Volume9,197,673 Change2.53%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Oct-16-18 03:48PM  AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status Zacks
06:30AM  U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer Business Wire
04:17AM  [$$] European Corporate News Roundup The Wall Street Journal
Oct-15-18 09:15AM  This is Why Merck (MRK) is a Great Dividend Stock Zacks
Oct-12-18 10:12AM  3 Large-Cap Pharma Stocks Performing Better Than Industry Zacks
09:12AM  Is This the Right Time to Enter Dow? 4 Great Picks Zacks
07:33AM  Bristol-Myers' Opdivo fails to meet lung cancer study goal Reuters
Oct-11-18 11:27PM  Edited Transcript of MRK earnings conference call or presentation 27-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
01:30PM  Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis CNW Group
07:30AM  Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:28AM  3 Stock Charts for Thursday: Apple, Merck and Verizon InvestorPlace
Oct-10-18 06:45AM  Merck to Hold Third-Quarter 2018 Sales and Earnings Conference Call on October 25 Business Wire
Oct-09-18 06:30AM  Mercks Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress Business Wire
Oct-08-18 05:43PM  Peninsula biotech coughs up 40 percent of its value on failed clinical trial American City Business Journals
11:24AM  [$$] Menlo Ends Development of Serlopitant in Refractory Chronic Cough The Wall Street Journal
08:56AM  5 Reasons Why Investors Should Bet on Merck (MRK) Stock Zacks
Oct-05-18 04:42PM  Merck Reports Positive Efficacy Data from Phase III HIV Study Zacks
Oct-04-18 10:10AM  Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report? Zacks
06:45AM  Mercks HIV Therapy DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens Business Wire
06:45AM  Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients Business Wire
Oct-03-18 08:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $20. ... GuruFocus.com
06:09PM  Merck CEO sees a disintermediation in pharma like the cable industry Yahoo Finance
09:32AM  Merck & Other Pharma Players Await FDA Decisions in October Zacks
Oct-02-18 05:20PM  Cancer center CEO leaves Merck board after disclosure scandal Reuters
04:53PM  Cancer center CEO leaves Merck board after disclosure scandal Reuters
04:14PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
09:48AM  Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed Zacks
09:30AM  Merck on Solid Footing This Year: Can it Sustain the Trend? Zacks
Oct-01-18 05:30PM  Genentech's first scientist now focused on Bay Area's latest biotech IPO American City Business Journals
04:01PM  Merck pledges $10M in national maternal health program American City Business Journals
12:30PM  Scientists behind game-changing cancer immunotherapies win Nobel medicine prize Reuters
08:43AM  Apple Was The Top Dow Jones Stock In Q3, But This Winner May Surprise You Investor's Business Daily
08:00AM  Merck Announces Safer Childbirth Cities Initiative, Issues Call to Action to Reverse the Rise in U.S. Maternal Deaths Business Wire
06:00AM  Merck May Rise by 15% to Highest Price Since 2001 Investopedia
Sep-27-18 09:03AM  Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks Zacks
07:41AM  The Zacks Analyst Blog Highlights: Amazon, Intel, Merck, Micron and Celgene Zacks
Sep-26-18 08:00PM  Gilead Sciences' Latest Tactic? Go Generic Motley Fool
06:14PM  Merck's Frazier to remain CEO of the U.S. drugmaker beyond 2019 Reuters
10:47AM  Top Analyst Reports for Amazon, Intel & Merck Zacks
09:15AM  Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice Zacks
08:11AM  Merck rescinds retirement policy; Frazier to remain CEO American City Business Journals
06:45AM  Merck Board Rescinds Mandatory CEO Retirement Policy Business Wire
Sep-24-18 02:40PM  OpGen signs deal with New York health department to research superbugs American City Business Journals
09:45AM  Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market Bloomberg
07:47AM  Merck subsidiary plans $48M investment, 115 jobs in Albany area over five years American City Business Journals
07:15AM  With An ROE Of 4.2%, Has Merck & Co Incs (NYSE:MRK) Management Done Well? Simply Wall St.
Sep-21-18 10:43AM  Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda Zacks
12:00AM  How Do Drugs Compete Against Each Other? Motley Fool
Sep-20-18 07:52PM  Flexible labs, co-working space: Big Pharma is rethinking real estate American City Business Journals
04:30PM  Merck Receives Positive CHMP Opinion for DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO (doravirine) in the European Union for the Treatment of HIV-1 Infection Business Wire
10:54AM  Merck or Pfizer: Which is the Better Large-Cap Pharma Stock? Zacks
08:25AM  Galectin stock lifts 15% premarket on early cancer combination trial results MarketWatch
08:00AM  Merck Publishes Corporate Responsibility Report PR Newswire
Sep-19-18 07:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ... GuruFocus.com
Sep-18-18 06:25PM  Accenture, Merck & Amazon AWS Partner for Cloud Platform Zacks
02:57PM  Health care ETF surges toward record in a broad sector rally MarketWatch
08:13AM  Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth? Zacks
Sep-14-18 10:02AM  Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus Zacks
08:39AM  Are Options Traders Betting on a Big Move in Merck (MRK) Stock? Zacks
07:21AM  Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal Zacks
Sep-13-18 10:44AM  Merck Gets Priority Review for Yet Another Keytruda sBLA Zacks
08:46AM  Is Merck & Co Incs (NYSE:MRK) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
07:21AM  Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck Bloomberg
Sep-12-18 09:55AM  Merck's Antibacterial Drug Succeeds in Label Expansion Study Zacks
09:45AM  Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus Zacks
09:43AM  Pfizer's Drug Combo Betters Survival in Kidney Cancer Study Zacks
08:34AM  The Zacks Analyst Blog Highlights: Merck, PepsiCo, 3M, Broadcom and Phillips 66 Zacks
06:45AM  FDA Grants Priority Review to Mercks Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS 1%) Business Wire
Sep-11-18 10:39AM  Top Stock Reports for Merck, PepsiCo & 3M Zacks
09:46AM  Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe Zacks
09:13AM  Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer Reuters
08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
06:45AM  Mercks ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Business Wire
Sep-10-18 09:36AM  Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod Zacks
08:04AM  The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson Zacks
07:23AM  Merck's Keytruda clocks up new win as EU approves chemo cocktail Reuters
06:45AM  European Commission Approves Mercks KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations Business Wire
Sep-07-18 10:41AM  Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus Zacks
10:26AM  Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA Zacks
08:35AM  Dow 30 Stock Roundup: Coca-Cola Buys Costa, DowDuPont Earnings Impress Zacks
08:00AM  Merck to Present at the Morgan Stanley 16th Annual Global Healthcare Conference Business Wire
Sep-06-18 02:12PM  These Hospital Systems Are Aiming To Undercut Biotechs, Drugmakers Investor's Business Daily
12:33PM  How This Player Helps Medical Researchers Ease Drug Discovery Process Investor's Business Daily
09:57AM  Large Cap Pharma Stocks Staging a Comeback in Second Half Zacks
06:30AM  Data from Mercks Leading Lung Cancer Research Program with KEYTRUDA® (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer Business Wire
Sep-05-18 08:05PM  [$$] Big Pharma Catches Up With Biotech The Wall Street Journal
04:17PM  This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen Investor's Business Daily
10:39AM  Merck's Keytruda Gets Priority Review for Rare Skin Cancer Zacks
07:26AM  [$$] Big Pharma Catches Up With Biotech The Wall Street Journal
06:45AM  Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA® (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC) Business Wire
Sep-04-18 09:19AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer Business Wire
Aug-31-18 03:53PM  Merck (MRK) Receives FDA Approval for Two HIV Medicines Zacks
12:42PM  The FDA Approves Merck's Anti-HIV-1 Drugs GuruFocus.com
10:19AM  Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus Zacks
08:39AM  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline Zacks
08:29AM  The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage Benzinga
Aug-30-18 04:45PM  FDA approves two new HIV drugs from Merck Reuters
04:19PM  FDA approves two new HIV drugs from Merck Reuters
04:05PM  FDA Approves Mercks DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., and Daiichi Sankyo Company, Limited. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM